Changes of MDR gene expression in patietns of gastric cancer undergoing neoadjuvant chemotherapy
10.3760/cma.j.issn.1007-631X.2009.05.005
- VernacularTitle:胃癌新辅助化疗前后多药耐药基因的表达及其与化疗敏感性的关系
- Author:
Yanqiang SONG
;
Yang LI
;
Huizhong LIN
;
Xinjian PANG
;
Linhao LI
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Muhidrug resistance-associated proteins;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of General Surgery
2009;24(5):365-367
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and sensitivity of 6 muhidmg resistance gene products(MDR) : GST-π、LRP、MRP、Topo Ⅱ、P-gp、TS in gastric cancer during neoadjuvant chemotherapy. Methods Expression of the 6 muhidrug resistance gene was detected by immunohistoehemistry in 35 cases of stomach cancer tissues before and after neoadjuvant chemotherapy. The relationship between muhidrug resistance gene and neoadjuvant chemotherapy was analyzed. All patients were given FOLFOX4, and the effects were evaluated according to World Health Organization criteria. Results The overall response rates to chemotherapy was 46%, expression of the 6 mtdtidrug resistance gene in 35 cases of stomach cancer tissues were as follows:GST-π was 40% ,LRP was 69% ,MRP was 34% ,Topo Ⅱ was 37% ,P-gp was 86%, TS was 40%, expression of the 6 muhidrug resistance gene did not change during neoadjuvant chemotherapy; GST-π、LRP、MRP、Topo Ⅱ、P-gp were not correlated with chemotherapy sensitivity(P > 0.05), while TS was significantly correlated with chemotherapy sensitivity (P = 0.0048). Conclusion FOLFOX4 does not effect a change in the expression of the 6 muhidrug resistance gene: GST-π、LRP、MRP、Topo Ⅱ、P-gp and TS, while TS is significantly correlated with gastric cancer chemotherapy sensitivity.
